Potent cyclic urea HIV protease inhibitors with benzofused heterocycles as P2/P2' groups

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 24, 1996, Pages 2919-2924

  Rodgers, James D ^a   Johnson, Barry L ^a   Wang, Haisheng ^a   Greenberg, Roger A ^a   Erickson Viitanen, Susan ^a   Klabe, Ronald M ^a   Cordova, Beverly C ^a   Rayner, Marlene M ^a   Lam, Gilbert N ^a   Chang, Chong Hwan ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,7 DIBENZYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[4 (HYDROXYMETHYL)BENZYL] 2H 1,3 DIAZEPIN 2 ONE; ANTIVIRUS AGENT; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; RAT;

EID: 0030591865     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(96)00531-8     Document Type: Article

References (20)

1. 1. For reviews see: (a) De Clercq, E. J. Med. Chem., 1995, 14, 2491;
2. (b) West, M. L.; Fairlie, D. P. Trends Pharmacol. Sci. 1995, 16, 67;
3. (c) Thaisrivongs, S. Annu. Rep. Med. Chem. 1994, 29, 133;
4. (d) Wlodawer, A.; Erickson, J. W. Annu. Rev. Biochem. 1993, 62, 543;
5. (e) Martin, J. A. Antiviral Res. 1992, 17, 265;
6. (f) Meek, T. D. J. Enzyme Inhib. 1992, 6, 65;
7. (g) Huff, J.R. J. Med. Chem. 1991, 34, 2305.
8. 2. (a) Danner, S. A.; Carr, A.; Leonard, J. M.; Leman, L. M.; Gudiol, F.; Gonzales, J.; Raventos, A.; Rubio, R.; Bouza, E.; Pintado, V.; Aguado, A. G.; De Lomas, J. G.; Delgado, R.; Borleffs, J. C. C.; Hsu, A.; Valdes, J. M.; Boucher, C. A. B.; Cooper, D. A. N. Engl. J. Med. 1995, 333, 1528.
9. (b) Markowitz, M.; Saag, M.; Powderly, W. G.; Hurley, A. M.; Hsu, A.; Valdes, J. M.; Henry, D.; Sattler, F.; La Marca, A.; Leonard, J. M.; Ho, D. D. N. Eng. J. Med. 1995, 333, 1534.
10. (c) Kitchen, V. S.; Skinner, C.; Ariyoshi, K.; Lane, E. A.; Duncan, I. B.; Burckhardt, J.; Burger, H. U.; Bragman, K.; Pinching, A. J.; Weber, J. N. The Lancet 1995, 345, 952.
11. 3. Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharp, T. R.; Erickson-Viitanen, S. Science 1994, 263, 380.
12. 4. Wong, Y. N.; Burcham, D. L.; Saxton, P. L.; Erickson-Viitanen, S.; Grubb, M. F.; Quon, C. Y.; Huang, S. M. Biopharm. Drug Dispos. 1994, 15, 535.
13. 5. Grubb, M. F.; Wong, Y. N.; Burcham, D. L.; Saxton, P. L.; Quon, C. Y.; Huang, S.-M. Drug Met. Disp. 1994, 22, 709.
14. 6. Lam, P. Y.; Ru, Y.; Jadhav, P. K.; Aldrich, P. E.; DeLucca, G. V.; Eyermann, C. J.; Chang, C. H.; Emmett, G.; Holler, E. R.; Daneker, W. F.; Li, L.; Confalonen P. N.; McHugh, R. J.; Li, R.; Markwalder, J. A.; Seitz, S. P.; Sharpe, T. R.; Bachelor, L. T.; Rayner, M. M.; Klabe, R. M.; Shum, L.; Winslow, D. L.; Kornhauser, D. M.; Jackson, D. A.; Erickson-Viitanen, S.; Hodge, C. N. J. Med. Chem. 1996, 39, 3514.
15. 7. Ki's were measured (n = 2) by assaying the cleavage of a fluorescent peptide substate using HPLC. Erickson-Viitanen, S.; Klabe, R. M.; Cawood, P. G.; O'Neal, P. L.; Meek, J. L. Antimicro. Agents Chemo. 1994, 38, 1628.
16. 90's were determined (n = 2) by measuring the accumulation of viral RNA transcripts three days after infection of MT-2 cells with HIV-1 RF. Bachelor, L. T.; Paul, M.; Jadhav, P. K.; Otto, M.; Stone, B.; Miller, J. Antiviral Chem. Chemother. 1994, 5, 111.
17. 9. C log P's were determined using ACD/Log P 1.0 by Advanced Chemistry Development Inc. Numbers in parentheses were determined by reverse phase HPLC.
18. 10. Ismail, I. A.; Sharp, D. E.; Chedekel, M. R. J. Org. Chem. 1980, 45, 2243.
19. 11. Biochemical Toxicology; A Practical Approach.; Snell, K.; Mullock, B., Eds.; IRL: Oxford, UK 1987
20. 12. Solubility was determined by reverse phase HPLC on filtrates of saturated solutions at pH 7.4.